NCT00418275已完成1 期
A Dose Finding, Pharmacokinetic and Safety Study of a Recombinant Human Plasminogen Activator (HTU-PA) in Patients With Acute Ischemic Stroke
Global Biotech2 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2001年4月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
- 试验地点
- 2
- 主要终点
- Major neurological improvement measured by NIHSS at 24 hours after treatment. "Major neurological improvement" is defined as 4-point improvement in the NIHSS measurement.
研究概览
简要总结
To evaluate the safety profiles of HTU-PA in patients with acute ischemic stroke.
详细描述
Cerebrovascular disease, the third leading cause of death after heart disease and cancer in developed countries, has an overall prevalence of 794 per 100,000. In the United States, it is estimated that more than 400,000 patients are discharged each year from hospitals after a stroke. The loss of these patients from the work force and the extended hospitalization they require during recovery make serious economic impact. In Taiwan, Cerebrovascular disease is the second cause of death.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects with cerebral ischemia at any location producing a serious measurable deficit by NIHSS scale and who received study medication within 5 hours after the onset of the symptom. A serious measurable deficit by NIHSS was defined as the NIHSS 9 and 20 (for brain stem stroke, patients with NIHSS > 20 were included).
- •Subjects were 18 years old, of either sex.
- •Subjects or his/her legal guardians demonstrated their willingness to participate in the study and comply with its procedures by signing a written informed consent.
- •Subjects with Modified Rankin Scale > 1.
排除标准
- •Onset of symptoms on awaking from sleep.
- •Intracranial bleeding detected on a pretreatment head computerized tomographic (CT) scan.
- •Clinical presentation suggested a subarachnoid hemorrhage even if the head CT scan was normal.
- •Head CT showed the evidence of early infarct sign > 1/3 of MCA territory.
- •Subjects had generalized seizure at the onset of the stroke.
- •Subjects with blood glucose < 50 mg/dl or > 400 mg/dl.
- •Subjects had another stroke, head trauma, cerebral hemorrhage or ischemic infarction within 3 months prior to the study entry.
- •Subjects with a significant surgery within 14 days prior to study entry.
- •Subjects with a history of gastrointestinal or urinary tract hemorrhage within 21 days prior to the study entry.
- •Subjects with lumbar puncture or arterial puncture of non-compressible site within 14 days prior to the study entry.
- •Subjects had known bleeding diathesis.
- •Subjects with other serious medical illness that interfered with the study.
- •Subjects had a platelet count < 100,000/mm3; hematocrit < 30%.
- •Subjects with other serious medical illness that interfered with the study.
- •Subjects had aPTT or PT > upper normal limit.
- •Subjects had uncontrolled hypertension (> 180 mmHg systolic or > 110 mmHg diastolic) without additional anti-hypertensive medication at screening visit.
- •Subjects with recent transmural myocardial infarction and evidence of pericarditis within 3 weeks prior to the enrollment.
- •Subjects had intracranial neoplasm, arteriovenous malformation, or aneurysm.
- •Subjects had hemostasis defects including secondary to severe hepatic or renal disease.
- •Subjects with history of drug or alcohol abuse within 1 year prior to the study entry.
- •Subjects had significant hepatic dysfunction (SGOT/SGPT 3 x upper normal limit).
- •Subjects had serum creatinine level 2 x upper normal limit or on renal dialysis.
- •Subjects had administration of any other investigational drug within 30 days prior to study entry.
- •Woman who was pregnant or nursing.
- •Subjects had used other thrombolytics (streptokinase, tissue plasminogen activator, urokinase, anisoylated plasminogen streptokinase activator complex, anticoagulants).
- •Subjects had severe cardiac disease (New York Heart Association Functional Classification III and IV).
- •Subjects had history of cancer except inactive non-melanoma skin cancer, in situ carcinoma of the cervix, or any cancer in patient's disease free for more than 5 years.
- •Subjects had any clinically significant deviation from normal in the physical examination that, in the investigator judgment, interfered with the study evaluation or affect subject safety.
- •Subjects with history of lupus.
- •Vasculitis was the cause of ischemic stroke.
- •Subjects had been enrolled in this study previously.
结局指标
主要结局
Major neurological improvement measured by NIHSS at 24 hours after treatment. "Major neurological improvement" is defined as 4-point improvement in the NIHSS measurement.
次要结局
- Major neurological improvement measured by NIHSS at 30 minutes, 60 minutes, 2 hours, 48 hours, 7 days, 30 days, and 90 days after treatment.
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Safety and Pharmacokinetic of Donepezil Pamoate in Healthy SubjectsADNCT03932916Shanghai Synergy Pharmaceutical Sciences Co., Ltd.38
招募中
2 期
To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric CancerStomach NeoplasmsSolid TumorNCT06504732SUNHO（China）BioPharmaceutical CO., Ltd.574
已完成
1 期
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid TumorsOvary CancerCervix CancerEndometrium CancerProstate Cancer (CRPC)Esophagus CancerLung Cancer(NSCLC)Bladder CancerSquamous Cell Carcinoma of the Head and Neck (SCCHN)NCT02001623Seagen Inc.195
招募中
1 期
A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors-JPRN-jRCT2080225128-6
已完成
2 期
A Pediatric Safety and Pharmacokinetics Study of Ha44 Gel Administered Topically for Treatment of Head Lice InfestationHead Lice InfestationNCT02010333Dr. Reddy's Laboratories Limited22